日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Molecular and cellular composition changes after neoadjuvant letrozole and palbociclib in early luminal breast cancer

早期管腔型乳腺癌新辅助治疗后分子和细胞组成的变化

Cottu, Paul; Kieffer, Yann; Lemonnier, Jerome; D'hondt, Véronique; Duhoux, Francois P; Callens, Céline; Gentien, David; Reyes, Cécile; Boulai, Anais; Desmoulins, Isabelle; Mouret-Reynier, Marie-Ange; Levy, Christelle; Heudel, Pierre-Etienne; Dalenc, Florence; Grenier, Julien; Fuhrmann, Laetitia; Baulande, Sylvain; Delaloge, Suzette; Mechta-Grigoriou, Fatima; Vincent-Salomon, Anne

Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer

新辅助帕博利珠单抗联合化疗治疗非转移性三阴性炎性乳腺癌,达到病理完全缓解

Lynce, F; Valenza, C; Niman, S M; Bertucci, F; Kai, M; Ryan, S; Troll, E; Layman, R M; Fanucci, K A; Giordano, A; Nasrazadani, A; Nakhlis, F; Bellon, J; Warren, L; Block, C; Schumer, S; Lucci, A; Krishnamurthy, S; Trapani, D; Lerebours, F; Dalenc, F; Levy, C; Petit, T; Leheurteur, M; Bachelot, T; Tredan, O; Ribeiro, J M; Pistilli, B; Zagami, P; Ladoire, S; Lopez Almeida, L; Zemmour, C; Carey, L A; Tolaney, S M; Valero, V; Curigliano, G; Regan, M M; Goncalves, A; Woodward, W A

Patritumab deruxtecan in HR(+)HER2(-) advanced breast cancer: a phase 2 trial

Patritumab deruxtecan治疗HR(+)HER2(-)晚期乳腺癌:一项II期试验

Pistilli, Barbara; Mosele, Fernanda; Corcos, Noemie; Pierotti, Livia; Pradat, Yoann; Le Bescond, Loic; Lacroix-Triki, Magali; Nachabeh, Ghada; Alfaro, Alexia; Catelain, Cyril; Job, Bastien; Mami-Chouaib, Fathia; Badel, Severine; Farace, Françoise; Oulhen, Marianne; Kannouche, Patricia; Tran, Diep T N; Droin, Nathalie; Vicier, Cecile; Frenel, Jean Sebastien; D'Hondt, Veronique; Dalenc, Florence; Bachelot, Thomas; Ducoulombier, Agnes; Benderra, Marc Antoine; Loirat, Delphine; Mayeur, Didier; Deluche, Elise; Deneuve, Jacqueline; Cheikh-Hussin, Rasha; Guyader, Pierre; Signolle, Nicolas; Godefroy, Karine; Talbot, Hugues; Vakalopoulou, Maria; Christodoulidis, Stergios; Bernard, Elsa; Koudou, Yves; Sporchia, Andrea; Suto, Fumitaka; Li, Lie; Sternberg, David W; Michiels, Stefan; André, Fabrice; Sellami, Dalila; Montagnac, Guillaume

Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial

在随机UNIRAD试验中,根据内分泌治疗方案的不同,辅助依维莫司治疗的获益存在差异

Saint-Ghislain, M; Chabaud, S; Dalenc, F; Allouache, D; Cameron, D; Martinez, M; Grenier, J; Barthelemy, P; Brunt, M; Kaluzinski, L; Mailliez, A; Legouffe, E; Hardy-Bessard, A-C; Giacchetti, S; Mouret-Reynier, M-A; Canon, J-L; Bliss, J; Lemonnier, J; Andre, F; Bachelot, T; Cottu, P

Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial

在PARSIFAL试验中,对帕博西尼联合氟维司群或来曲唑治疗内分泌敏感、激素受体阳性/HER2阴性晚期乳腺癌患者进行了延长随访。

Llombart-Cussac, A; Pérez-García, J M; Bellet, M; Dalenc, F; Gil-Gil, M; Ruiz-Borrego, M; Gavila, J; Schmid, P; Zamora, P; Wheatley, D; Martínez-de Dueñas, E; Amillano, K; Di Cosimo, S; Anton, A; Cottu, P; Shimizu, E; Fernandez, M; Sampayo-Cordero, M; Cortés, J

Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort

ESME-MBC队列中HR阳性/HER2阴性转移性乳腺癌患者在接受CDK4/6抑制剂治疗后疾病进展的真实世界治疗模式和疗效

Varnier, R; Pérol, D; Jacot, W; Mailliez, A; Diéras, V; Dalenc, F; Gonçalves, A; Levy, C; Arnedos, M; Frenel, J-S; Bailleux, C; Massard, V; Brain, E; Sauterey, B; Savoye, A-M; Bosquet, L; Thery, J-C; Petit, T; Bachelot, T; Grinda, T; Ray-Coquard, I

PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort

PROMENADE:帕博利珠单抗治疗早期ER低表达/HER2阴性乳腺癌,法国真实世界队列研究

Cherifi, F; Cabel, L; Bousrih, C; Volant, E; Dalenc, F; Mery, B; Auvray Kuentz, M; Mailliez, A; Ladoire, S; de Nonneville, A; Alexandre, M; Benistant, L; Leheurteur, M; Bailleux, C; Debled, M; Frenel, J-S; Loirat, D; Bastien, E; Aussedat, Q; Bidard, F C; Aho, S; Glenet, A; Mourato-Ribeiro, J; Johnson, A; Christy, F; Emile, G

Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial

内分泌辅助治疗起始时间与高危早期乳腺癌患者无病生存期之间的关联:UCBG-UNIRAD试验子研究结果

Giacchetti, Sylvie; Laas, Enora; Bachelot, Thomas; Lemonnier, Jérome; André, Fabrice; Cameron, David; Bliss, Judith; Chabaud, Sylvie; Hardy-Bessard, Anne-Claire; Lacroix-Triki, Magali; Canon, Jean-Luc; Debled, Marc; Campone, Mario; Cottu, Paul; Dalenc, Florence; Ballesta, Annabelle; Penault-Llorca, Frederique; Asselain, Bernard; Dumas, Elise; Reyal, Fabien; Gougis, Paul; Lévi, Francis; Hamy, Anne-Sophie

Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

紫杉醇联合可溶性 LAG-3 蛋白 Eftilagimod Alpha 治疗转移性 HR+ 乳腺癌:AIPAC 随机、安慰剂对照 IIb 期试验的结果

Wildiers, Hans; Armstrong, Anne; Cuypere, Eveline; Dalenc, Florence; Dirix, Luc; Chan, Steve; Marme, Frederik; Schröder, Carolina P; Huober, Jens; Duhoux, Francois P; Vuylsteke, Peter; Jager, Agnes; Brain, Etienne; Kuemmel, Sherko; Pápai, Zsuzsanna; Menke-van der Houven van Oordt, Catharina Willemien; Perjesi, Luca; Mueller, Christian; Brignone, Chrystelle; Triebel, Frederic

Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer

在接受曲妥珠单抗-德鲁西替康治疗后,图卡替尼联合治疗ERBB2阳性转移性乳腺癌患者

Frenel, Jean-Sebastien; Zeghondy, Jean; Guérin-Charbonnel, Catherine; Mailliez, Audrey; Volant, Elsa; Poumeaud, François; Patsouris, Anne; Arnedos, Monica; Bailleux, Caroline; Cabal, Julie; Galland, Loick; de Nonneville, Alexandre; Guiu, Séverine; Dalenc, Florence; Pistilli, Barbara; Bachelot, Thomas; Pierga, Jean-Yves; Le Du, Fanny; Bocquet, François; Larrouquere, Louis; Loirat, Delphine